Polymeric Theranostics with Tetraphenylporphyrin for Effective Low-Dose Photodynamic Cancer Therapy
Pharmaceutics · 27.04.2026 · 18 (5) · 531
DOI: 10.3390/pharmaceutics18050531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.04.2026. Verfasst von Alžběta Turnovská und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 00 Prague, Czech Republic. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education Youth and Sports, National Institute for Cancer Research, European Union-Next Generation EU.
Abstract (Originalsprache)
Background/Objectives: Photodynamic therapy (PDT) relies on light activation of photosensitizers to generate reactive oxygen species for tumor ablation; however, limited tumor selectivity and systemic toxicity of free photosensitizers remain challenges. This study aimed to develop polymer-based nanotheranostics carrying tetraphenylporphyrin (TPPc) derivatives and to evaluate how linker structure impacts their performance.
Methods
TPPc derivatives were covalently conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymers via either pH-sensitive hydrazone linkages (using aliphatic 5-hydroxy-2-pentanone or aromatic 1-(4-hydroxymethyl)phenyl)ethanone spacer) or stable amide bonds, forming amphiphilic polymer conjugates. The conjugates were characterized based on their physicochemical and in vitro and in vivo biological behavior.
Results
Polymer conjugation reduced dark toxicity while preserving photodynamic activity. Linker structure influenced intracellular behavior and singlet oxygen production, with hydrazone systems showing faster activation-related responses under acidic conditions in vitro. All conjugates accumulated in tumors and induced significant tumor growth inhibition after irradiation at low doses (2.5 mg kg−1 TPPc equivalent), while the amide-linked conjugate showed the strongest overall in vivo therapeutic effect, likely due to more favorable biodistribution and sustained delivery.
Conclusions
The developed HPMA-based polymer–TPPc conjugates improve the therapeutic profile of photosensitizers by reducing toxicity and enabling effective PDT. These findings highlight the importance of linker design in balancing photosensitizer activation, circulation stability, and biodistribution, which together determine the overall therapeutic outcome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 00 Prague, Czech Republic.
- Laboratory of Microbiology and Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto 860-0082, Japan.
- Institute of Inorganic Chemistry, Czech Academy of Sciences, 250 68 Husinec-Řež, Czech Republic.
- Department of Toxicology, School of Public Health, Anhui Medical University, Hefei 230032, China.
ORCID-Profile: Alžběta Turnovská, Marina Rodrigues Tavares, Jan Hynek, Kamil Lang, Tomáš Etrych
Förderung
- Ministry of Education Youth and Sports
- National Institute for Cancer Research
- European Union-Next Generation EU
- Bilateral Joint Research Project between the Japan Society for the Promotion of Science (JSPS) and the Czech Academy of Sciences
Zitieren
APA
Turnovská, A., Gao, S., Tavares, M. R., Hynek, J., Lang, K., Fang, J., & Etrych, T. (2026). Polymeric Theranostics with Tetraphenylporphyrin for Effective Low-Dose Photodynamic Cancer Therapy. Pharmaceutics, 18(5), 531. https://doi.org/10.3390/pharmaceutics18050531
Vancouver
Turnovská A, Gao S, Tavares MR, Hynek J, Lang K, Fang J, et al. Polymeric Theranostics with Tetraphenylporphyrin for Effective Low-Dose Photodynamic Cancer Therapy. Pharmaceutics. 2026;18(5):531. doi:10.3390/pharmaceutics18050531
BibTeX
@article{Turnovsk2026,
author = {Turnovská, Alžběta and Gao, Shanghui and Tavares, Marina Rodrigues and Hynek, Jan and Lang, Kamil and Fang, Jun and Etrych, Tomáš},
title = {Polymeric Theranostics with Tetraphenylporphyrin for Effective Low-Dose Photodynamic Cancer Therapy},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {531},
doi = {10.3390/pharmaceutics18050531}
}
EUVIMED